HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
<br /> | <br /> | ||
{| class="wikitable sortable" style="margin:auto" | {| class="wikitable sortable" style="margin:auto" | ||
|+<big> | |+<big>cWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big> | ||
|- | |- | ||
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) | !Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition) | ||
| Line 1,656: | Line 1,656: | ||
|- | |- | ||
|RESOLVE 4th edition ALL-Related NON-WHO entities content | |RESOLVE 4th edition ALL-Related NON-WHO entities content | ||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | ||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | |||
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | |||
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | |||
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | |||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | |||
|ISSUE- FIX | |ISSUE- FIX | ||
| Line 1,673: | Line 1,688: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | ||
| Line 2,359: | Line 2,390: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo; | |||
Zhenya Tang | |||
|4/14/25||7/14/25 | |||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo; | |||
Zhenya Tang | |||
|4/14/25||7/14/25 | |||
9/4/2025 Sent E-mail reminder to Dr. Tang | |||
|Pending|| ||SG | |||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | | ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | ||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
| Line 2,413: | Line 2,428: | ||
|Prior Date of Last Editor Review (4th Edition) | |Prior Date of Last Editor Review (4th Edition) | ||
|Prior Notes (4th Edition) | |Prior Notes (4th Edition) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||
| Line 2,510: | Line 2,541: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); | |||
Michelle Don, MD, MS | |||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); | |||
Michelle Don, MD, MS | |||
|3/17/2024 (trainee name added on 9/9/24 by JH) | |3/17/2024 (trainee name added on 9/9/24 by JH) | ||
|6/30/24 | |6/30/24 | ||
| Line 2,580: | Line 2,595: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident) | |[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident) | ||
| Line 2,635: | Line 2,666: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | |||
|3/19/2024 | |||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | |||
|3/19/2024 | |||
| ||Pending | | ||Pending | ||
| ||SK|| || | | ||SK|| || | ||
| Line 2,689: | Line 2,704: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | |[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | ||
| Line 2,745: | Line 2,776: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | |||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | |||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
|6/6/24|| ||Pending | |6/6/24|| ||Pending | ||
| Line 2,794: | Line 2,809: | ||
| | | | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| Line 2,854: | Line 2,885: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | |[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | ||
| Line 2,895: | Line 2,910: | ||
|11/21/2021 | |11/21/2021 | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||